Neumora Therapeutics (NMRA) Research & Development (2022 - 2026)

Neumora Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $38.6 million for Q1 2026.

• In Q1 2026, Research & Development fell 25.99% year-over-year to $38.6 million; the TTM figure through Mar 2026 stood at $162.5 million (down 21.61% YoY), while the FY2025 annual figure was $176.1 million, down 12.37% from the prior year.
• Research & Development was $38.6 million for Q1 2026 at Neumora Therapeutics, down from $44.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $60.6 million in Q3 2024 to a low of $22.5 million in Q3 2022.
• Historically, Research & Development has averaged $40.3 million across 5 years, with a median of $40.5 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Research & Development surged 84.49% in 2023, then slumped 33.17% in 2025.
• A 5-year view of Research & Development shows it stood at $23.5 million in 2022, then surged by 65.22% to $38.9 million in 2023, then grew by 18.14% to $45.9 million in 2024, then slipped by 2.71% to $44.7 million in 2025, then dropped by 13.59% to $38.6 million in 2026.
• The last three Research & Development figures came in at $38.6 million (Q1 2026), $44.7 million (Q4 2025), and $40.5 million (Q3 2025), per Business Quant data.